Compare Abeona Therapeutics Inc (ABEO) vs AGNC Investment Corp (AGNC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abeona Therapeutics Inc vs AGNC Investment Corp — how do they compare? Abeona Therapeutics Inc trades at $7.4 (market cap $421.19M), while AGNC Investment Corp trades at $10.96 (market cap $12.91B). The key difference: AGNC Investment Corp is far larger — about 30.7× Abeona Therapeutics Inc's market cap, and AGNC Investment Corp pays a 13.22% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | AGNC | |
|---|---|---|
Market Cap | $421.19M | $12.91B |
Sector | Health | Financials |
52-Week High | $7.45 | $12.17 |
52-Week Low | $4.17 | $9.46 |
Enterprise Value | $276.10M | — |
Dividend Yield | — | 13.22% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.365, down 1.14% today, amid a bullish technical outlook with moving averages signaling strength. The company reported a net income of $71.18 million in 2025, with a net margin of 454.86%, though revenue remains modest at $5.82 million. Recent news includes CMS granting NTAP status for ZEVASKYN and expanding its treatment center network, indicating commercial progress.
The outlook is supported by strong analyst consensus (66.7% buy ratings) and robust profitability metrics, but risks include high SG&A expenses relative to revenue and a shareholder investigation. Upside hinges on revenue scaling to justify current valuations, with the Q2 2026 earnings call on August 13, 2026, as a key near-term catalyst.
AGNC Investment Corp. trades at $10.76, down 0.74% on the day, with a bullish technical signal from moving averages and a neutral stance from oscillators. The mortgage REIT reported strong profitability with a net income margin of 94.38% and ROE of 21.67% for 2025, while recent earnings beat expectations in Q1 and Q2 2026. Analysts maintain a consensus price target of $11.30, with 31% recommending Buy, though the majority (60%) suggest Hold.
AGNC offers a high dividend yield, supported by consistent payouts, but faces risks from interest rate sensitivity and leveraged mortgage securities. Upside potential exists if stable spreads persist, yet the stock's valuation above book value requires careful monitoring of portfolio performance and macroeconomic conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About AGNC Investment Corp
AGNC Investment Corp is a real estate investment trust that invests in agency residential mortgage-backed securities. The firm's asset portfolio is comprised of residential mortgage pass-through securities and collateralized mortgage obligations for which the principal and interest payments are guaranteed by a U.S. Government-sponsored enterprise, such as the Federal National Mortgage Association and the Federal Home Loan Mortgage Corporation, or by a U.S. Government agency, such as the Government National Mortgage Association. It also invests in other types of mortgage and mortgage-related residential and commercial mortgage-backed securities or other investments in or related to, the housing, mortgage or real estate markets.
Read more on AGNC →
